NASDAQ:VICL - Vical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.44 +0.05 (+3.60 %)
(As of 09/25/2018 04:00 PM ET)
Previous Close$1.39
Today's Range$1.39 - $1.44
52-Week Range$1.02 - $3.70
Volume48,000 shs
Average Volume185,225 shs
Market Capitalization$31.42 million
P/E Ratio-1.42
Dividend YieldN/A
Vical logoVical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL News and Ratings via Email

Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio16.89
Quick Ratio16.89


Trailing P/E Ratio-1.42
Forward P/E Ratio-1.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.82 million
Price / Sales2.27
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book0.42


EPS (Most Recent Fiscal Year)($1.01)
Net Income$-12,960,000.00
Net Margins-207.71%
Return on Equity-33.70%
Return on Assets-28.93%


Outstanding Shares21,820,000
Market Cap$31.42 million

Vical (NASDAQ:VICL) Frequently Asked Questions

What is Vical's stock symbol?

Vical trades on the NASDAQ under the ticker symbol "VICL."

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The biotechnology company had revenue of $0.74 million for the quarter, compared to analysts' expectations of $0.51 million. Vical had a negative net margin of 207.71% and a negative return on equity of 33.70%. View Vical's Earnings History.

When is Vical's next earnings date?

Vical is scheduled to release their next quarterly earnings announcement on Monday, October, 22nd 2018. View Earnings Estimates for Vical.

What price target have analysts set for VICL?

1 Wall Street analysts have issued twelve-month price objectives for Vical's stock. Their predictions range from $4.00 to $4.00. On average, they anticipate Vical's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for Vical.

What is the consensus analysts' recommendation for Vical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vical.

Are investors shorting Vical?

Vical saw a drop in short interest in August. As of August 31st, there was short interest totalling 309,897 shares, a drop of 78.3% from the August 15th total of 1,425,698 shares. Based on an average trading volume of 87,978 shares, the days-to-cover ratio is currently 3.5 days. Currently, 1.6% of the company's shares are short sold. View Vical's Current Options Chain.

Who are some of Vical's key competitors?

Who are Vical's key executives?

Vical's management team includes the folowing people:
  • Mr. Vijay B. Samant, CEO, Pres & Director (Age 65)
  • Mr. Anthony Alan Ramos, VP, CFO & Chief Accounting Officer (Age 51)
  • Dr. Lawrence Russell Smith, Sr. VP of Research (Age 57)
  • Dr. Mammen P. Mammen Jr., Sr. VP of Clinical Devel. (Age 54)

Who are Vical's major shareholders?

Vical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.02%), BlackRock Inc. (1.81%) and Acadian Asset Management LLC (0.82%). Company insiders that own Vical stock include Anthony Alan Ramos, Armistice Capital Master Fund, Armistice Capital, Llc, Lawrence Russell Smith, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Institutional Ownership Trends for Vical.

Which institutional investors are buying Vical stock?

VICL stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC and BlackRock Inc.. Company insiders that have bought Vical stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc and Robert C Merton. View Insider Buying and Selling for Vical.

How do I buy shares of Vical?

Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical's stock price today?

One share of VICL stock can currently be purchased for approximately $1.44.

How big of a company is Vical?

Vical has a market capitalization of $31.42 million and generates $13.82 million in revenue each year. The biotechnology company earns $-12,960,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Vical employs 74 workers across the globe.

What is Vical's official website?

The official website for Vical is

How can I contact Vical?

Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected]

MarketBeat Community Rating for Vical (NASDAQ VICL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel